These approaches have led to significant weight loss with the dual GLP-1/glucagon receptor agonist survodutide (-13.5% with the 6-mg dose at 76 weeks in a phase 3 SYNCHRONIZE-1 trial) [16] , the dual GLP-1 receptor agonist and GIP antagonist Maridebart cafraglutide (known as MariTide) (-12.3% to -16.2% across different doses at 52 weeks in a phase 2 trial) [17] or the triple GLP-1/GIP/glucagon receptor agonist retatrutide (-24.2% with the 12-mg dose at 48 weeks in a phase 2 trial) [18]
Smirnov D, Eremenko E, Stein D, et al
Neurochem Res 15:597601 Ricciolini R, Scalibastri M, Kelleher JK, Carminati P, Calvani M, Arduini A (1998) Role of acetyl-l-carnitine in rat brain lipogenesis: implications for polyunsaturated fatty acid biosynthesis
In Ethiopian varieties, the content can exceed 480 mg/100 g ( A
They are always so friendly and informative, and the staff is amazing
More recently oral glutathione has been investigated for its use in the treatment of NAFLD